Summit Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Summit Therapeutics

23/07/2026 22:03

Summit Therapeutics Inc SMMT.OQ reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -12 cents.  The mean expectation of seventeen analysts for the quarter was for a loss of 28 cents per share. Wall Street expected results to range from -47 cents to -15 cents per share.
Reported revenue was zero​; analysts expected zero. 
Summit Therapeutics Inc's reported EPS for the quarter was a loss of 28 cents​.
The company reported a quarterly loss of $215.7 million.
Summit Therapeutics Inc shares had risen by 1.2% this quarter and lost 15.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 41.3% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 5 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Summit Therapeutics Inc is $33.00, about 55.3% above its last closing price of $14.74
This summary was machine generated from LSEG data July 23 at 09:03 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.28
-0.28
Met
Mar. 31 2026 
-0.18
-0.24
Missed
Dec. 31 2025 
-0.06
-0.29
Missed
Sep. 30 2025 
-0.13
-0.31
Missed